Global Information
회사소개 | 문의 | 비교리스트

BERCOLAGENE TELSERPAVEC(KB103) : 신약 인사이트와 시장 예측(2030년)

BERCOLAGENE TELSERPAVEC (KB103)- Emerging Drug Insight and Market Forecast - 2030

리서치사 DelveInsight Business Research LLP
발행일 2020년 09월 상품 코드 959706
페이지 정보 영문 50 Pages
US $ 3,250 ₩ 3,819,000 PDF (Single User License)
US $ 6,500 ₩ 7,638,000 PDF (Site License)
US $ 9,750 ₩ 11,458,000 PDF (Global License)

BERCOLAGENE TELSERPAVEC(KB103) : 신약 인사이트와 시장 예측(2030년) BERCOLAGENE TELSERPAVEC (KB103)- Emerging Drug Insight and Market Forecast - 2030
발행일 : 2020년 09월 페이지 정보 : 영문 50 Pages

B-VEC는 Krystal의 주요 제품 후보이며, 유전자 치료를 사용해 이영양성수포성표피박리증(DEB) 치료를 목표로 하고 있습니다. 이것은 피부 콜라겐 결여에 의해 발생하는 불치의 피부수포질환입니다. B-VEC는 Krystal의 STAR-D 플랫폼을 사용하고, 기능적인 인간 COL7A1 유전자를 환자의 분열 및 비분열 피부 세포에 직접 전달하는 복제 결함이 있는 비통합형 바이러스 벡터입니다. Krystal의 HSV-1는 다른 바이러스 벡터보다 효율적으로 피부 세포에 침입할 수 있는 독자적인 벡터입니다. 그 높은 페이로드 용량이 큰 또는 다수의 유전자에 대응하는 것을 가능하게 하고, 그 낮은 면역원성으로 인해 피부로의 직접 및 반복 전달에 적절한 선택입니다.

미국, 유럽 5개국(독일, 프랑스, 이탈리아, 스페인, 영국) 및 일본 7개 주요 시장의 BERCOLAGENE TELSERPAVEC(KB103)에 대해 상세하게 설명하고(작용기서, 투여량, 합성 경로, 규제 마일스톤을 포함한 연구개발 활동 및 기타 개발 활동), SWOT 분석, 시장 경쟁사 및 기타 새로운 치료법을 포함한 향후 시장 평가를 제공합니다.


제1장 의약품 개요

  • 제품 상세
  • 작용기서
  • 투약과 관리
  • 연구개발 활동
    • 임상 개발
    • 안전성과 유효성
  • 기타 개발 활동

제2장 시장 평가

  • 주요 7개국 시장 분석
  • 미국 시장
  • 독일 시장
  • 프랑스 시장
  • 이탈리아 시장
  • 스페인 시장
  • 영국 시장
  • 일본 시장

제3장 SWOT 분석

제4장 애널리스트의 견해

제5장 시장 경쟁사

제6장 기타 새로운 치료법

제7장 부록

제8장 보고서 구입 옵션

KSM 20.09.16

List of Tables

  • Table 1 BERCOLAGENE TELSERPAVEC (KB103), Description
  • Table 2 BERCOLAGENE TELSERPAVEC (KB103), Clinical Trial Description
  • Table 3 BERCOLAGENE TELSERPAVEC (KB103), 7MM Market Size from 2020 to 2030 (in Million USD)
  • Table 4 Market Competitors
  • Table 5 Other Emerging Therapies

List of Figures

  • Figure 1 The Development Timeline of BERCOLAGENE TELSERPAVEC (KB103)
  • Figure 2 Patent Details, BERCOLAGENE TELSERPAVEC (KB103)
  • Figure 3 BERCOLAGENE TELSERPAVEC (KB103), 7MM Market Size from 2020 to 2030 (in Million USD)
  • Figure 4 BERCOLAGENE TELSERPAVEC (KB103), US Market Size from 2020 to 2030 (in Millions USD)
  • Figure 5 BERCOLAGENE TELSERPAVEC (KB103), EU5 Market Size from 2020 to 2030 (in Millions USD)
  • Figure 6 BERCOLAGENE TELSERPAVEC (KB103), Japan Market Size from 2020 to 2030 (in Millions USD)

"BERCOLAGENE TELSERPAVEC (KB103)- Emerging Drug Insight and Market Forecast - 2030" the report provides comprehensive insights about an investigational product for Epidermolysis bullosa in 7 Major Markets. A detailed picture of the BERCOLAGENE TELSERPAVEC (KB103) in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2020-2030 is provided in this report along with a detailed description of the product. The product details cover mechanism of action, dosage and administration, route of synthesis, and Research and development activity including regulatory milestones, and other development activities. Further, it also consists of future market assessments inclusive of the market forecast, SWOT analysis, market competitors, and other emerging therapies.

Drug Summary:

B-VEC is Krystal's lead product candidate that seeks to use gene therapy to treat dystrophic epidermolysis bullosa, or DEB, an incurable skin blistering condition caused by a lack of collagen in the skin. B-VEC is a replication-defective, non-integrating viral vector employing Krystal's STAR-D platform to deliver functional human COL7A1 genes directly to the patients' dividing and non-dividing skin cells. Krystal's HSV-1 is a proprietary vector that can penetrate skin cells more efficiently than other viral vectors. Its high payload capacity allows it to accommodate large or multiple genes and its low immunogenicity makes it a suitable choice for direct and repeat delivery to the skin.

Scope of the report:

The report provides insights into:

  • A comprehensive product overview including the product description, mechanism of action, dosage and administration, Research and Development activity.
  • Elaborated details on regulatory milestones and other development activities have been provided in this report.
  • The report also highlights the drug research and development activity details across the United States, Europe and Japan.
  • The report also covers the patents information with expiry timeline around BERCOLAGENE TELSERPAVEC (KB103).
  • The report contains forecasted sales for BERCOLAGENE TELSERPAVEC (KB103) till 2030.
  • Comprehensive coverage of the late-stage emerging therapies (Phase III) for Epidermolysis bullosa.
  • The report also features the SWOT analysis with analyst insights and key findings of BERCOLAGENE TELSERPAVEC (KB103).


The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

BERCOLAGENE TELSERPAVEC (KB103) Analytical Perspective by DelveInsight

  • In-depth BERCOLAGENE TELSERPAVEC (KB103) Market Assessment

This report provides a detailed market assessment of BERCOLAGENE TELSERPAVEC (KB103) in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2020 to 2030.

  • BERCOLAGENE TELSERPAVEC (KB103) Clinical Assessment

The report provides the clinical trials information of BERCOLAGENE TELSERPAVEC (KB103) covering trial interventions, trial conditions, trial status, start and completion dates.

Report highlights:

  • In the coming years, the market scenario for Epidermolysis bullosa is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence BERCOLAGENE TELSERPAVEC (KB103) dominance. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Other emerging products for Epidermolysis bullosa are giving market competition to BERCOLAGENE TELSERPAVEC (KB103) and launch of late-stage emerging therapies in the near future will significantly impact the market.
  • A detailed description of regulatory milestones, development activities, and some key findings provide the current development scenario of BERCOLAGENE TELSERPAVEC (KB103).
  • Our in-depth analysis of the forecasted sales data of BERCOLAGENE TELSERPAVEC (KB103) from 2020 to 2030 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the BERCOLAGENE TELSERPAVEC (KB103).

Key Questions:

  • Which company is developing BERCOLAGENE TELSERPAVEC (KB103) along with the phase of the clinical study?
  • What is the technology utilized in the development of BERCOLAGENE TELSERPAVEC (KB103)?
  • What is the product type, route of administration and mechanism of action of BERCOLAGENE TELSERPAVEC (KB103)?
  • What is the clinical trial status of the study and study completion date?
  • What are the key collaborations, mergers and acquisitions, licensing and other activities related to the BERCOLAGENE TELSERPAVEC (KB103) development?
  • What are the key designations that have been granted to BERCOLAGENE TELSERPAVEC (KB103)?
  • What is the forecasted market scenario of BERCOLAGENE TELSERPAVEC (KB103)?
  • What is the history of BERCOLAGENE TELSERPAVEC (KB103) and what is its future?
  • What is the forecasted sales of BERCOLAGENE TELSERPAVEC (KB103) in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
  • What are the other emerging products available and how these are giving competition to BERCOLAGENE TELSERPAVEC (KB103)?
  • Which are the late-stage emerging therapies under development for the treatment of the PPD?

Table of Contents

1. Drug Overview

  • 1.1. Product Detail
  • 1.2. Mechanism of Action
  • 1.3. Dosage and Administration
  • 1.4. Research and development activity
    • 1.4.1. Clinical Development
    • 1.4.2. Safety and Efficacy
  • 1.5. Other Development Activities

2. Market Assesment

  • 2.1. 7MM Market Analysis
  • 2.2. The United States Market
  • 2.3. Germany Market
  • 2.4. France Market
  • 2.5. Italy Market
  • 2.6. Spain Market
  • 2.7. United Kingdom Market
  • 2.8. Japan Market

3. SWOT Analysis

4. Analyst Views

5. Market Competitors

6. Other Emerging Therapies

7. Appendix

8. Report Purchase Options

Back to Top
전화 문의